Caldera Medical Awarded Contract Agreement With Premier Inc.

Caldera Medical has begun operating under the terms of a national group purchasing agreement for Surgical Incontinence and Specialty Women’s Health Products with Premier Inc.

The new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier. This initiative underscores Caldera’s continued increase in investment to provide Premier facilities a commitment to consistent supply and a strong focus on domestic manufacturing.
 
Premier is a healthcare improvement company, uniting an alliance of approximately 4,350 U.S. hospitals and 300,000 other providers. With integrated data and analytics, collaboratives, supply chain solutions, consulting and other services, Premier enables better care and outcomes at a lower cost.
 
Caldera is offering its portfolio of Vertessa implants for pelvic organ prolapse and Desara slings as well as its reusable introducers for stress urinary incontinence. The reusable instruments drive sustainability by reducing medical waste and standardizing surgical supplies. Caldera’s product line is expected to decrease SKU numbers by at least 33%, significantly optimizing inventory management processes and reducing inventory holding costs. These innovations not only help improve efficiency, they also help provide relief to women suffering from stress urinary incontinence and pelvic organ prolapse.
 
Further enhancing Caldera’s product portfolio is Benesta, a state-of-the-art, battery-powered device engineered to treat polyps and fibroids. Featuring user-friendly push-button hand activation and an enlarged cutting window, Benesta sets a new standard in ease of use and effectiveness. It is universally compatibile with all scopes and fluid management systems.
 
Caldera Medical is a medical device company solely focused on women’s health. It develops, manufactures, and markets surgical products for treating stress urinary incontinence, pelvic organ prolapse, polyps, and fibroids. Caldera Medical is dedicated to treating 1 million women globally in underserved populations by 2027.